BioSpace

With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys

After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squibb, which spent $14 billion for Karuna just two weeks later.

By BioSpace

1 min read
With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights